1970 Ph.D., Adelaide University, South Australia
1966 B.Sc., Adelaide University, South Australia
Area(s) of Interest
Analytical and Protein Chemistry
Prof. Hancock is the founding Editor-in-Chief of the ACS publication, Journal of Proteomic Research, which is a leading journal publishing research in related areas of functional genomics, proteomic methodological research, disease and agricultural proteomics as well as metabanomics. Prof. Hancock’s research is focused on applying new analytical technology to current problems in the biotechnology industry as well as cancer proteomics and the plasma proteome.
Also Prof. Hancock is a co-leader of an international, collaborative initiative called the chromosome-centric human proteome project (C-HPP) which has enlisted 24 national teams, each focusing their efforts on the proteins contained on a single chromosome — each of which contains hundreds to thousands of genes. Also Dr. Hancock’s team, which includes Stanford, Michigan and Manitoba University, will characterize the proteins on chromosome number 17, including the important breast cancer gene, ERBB2. Ultimately, the goal is to have a full protein database within ten years, which will help clinicians analyze a patient’s true biological state and design targeted therapies for their conditions. In 2012, the Journal of Proteome Research published a special issue which contained 35 papers describing progress by the chromosome teams and in 2013 there have been dedicated chromosome meetings in Berlin and Yokohama with further progress on the initial phase of the project. In conclusion, the initiative has been launched, and the momentum has been very strong with substantial global resources committed to the project.
420 The Fenway
Dr. William Hancock, the Bradstreet Chair in Chemistry and Chemical Biology and an expert in protein drugs, has been invited to serve as a consultant as a consultant to the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA).